Anti-CML Human autoAntibody ELISA Kit

Name: Anti-CML Human autoAntibody ELISA Kit
SKU: DEIABL518
Rating: 5 (1 reviews)

Regulatory status: For research use only, not for use in diagnostic procedures.

COA

SDS

Datasheet

Summary

Sample

serum, plasma

Species Reactivity

Human

Intended Use

The Anti-CML human autoantibody ELISA Kit is used for the semi-quantitative measurement of IgG class anti-CML/Nε-(carboxymethyl) lysine human autoantibody in human serum and plasma.

Storage

- Upon receipt store all components at 4°C.
- Don't expose reagents to excessive light.

Precision

Intra-assay (Within-Run, n=8) CV=5.6 %
Inter-assay (Run-to-Run, n=4) CV=8.7 %

Sensitivity

The limit of detection (defined as such a concentration of anti-CML antibody giving absorbance lower than mean absorbance plus three standard deviations of the absorbance of Blank: Blank + 3*SD Blank) is better than 0.16 ng/mL of sample.

General Description

Reducing sugars react with protein amino groups to form a diverse group of protein-bound moieties with fluorescent and cross-linking properties. These compounds, called advanced glycosylation end products (AGEs), have been implicated in the structural and functional alterations of proteins that occur during aging and long-term diabetes. Although several AGE structures have been reported, it was demonstrated that Nε -(carboxymethyl) lysine (CML) is a major antigenic AGE structure. CML concentration is also increased in patients who have diabetes with complications, including nephropathy, retinopathy, and atherosclerosis. CML is also recognized by receptor for AGE (RAGE), and CML-RAGE interaction activates cell signaling pathways such as NF-B and enhances the expression of vascular cell adhesion molecule-1 in human umbilical vein endothelial cells. It has been postulated that AGE structures present in vivo could serve as an immunological epitope to raise autoantibodies against AGE structures, particularly CML. Shibayama et al. showed the presence of autoantibodies agaist AGE structures, particularly those against CML adduct in streptozotocin (STZ)-induced diabetic rats and patients with several diseases. The autoantibody against CML adduct was higher in patients with renal failure than in normal subjects or diabetic patients without renal failure. These results suggest that autoantibody against CML might play a possible role in the development of diabetic nephropathy or chronic renal failure.

Citations

Have you cited DEIABL518 in a publication? Let us know and earn a reward for your research.

Documents

pdf COA

pdf SDS

pdf Datasheet

QA & Reviews

Customer Reviews

References

Wilms' tumor 1 gene in hematopoietic malignancies: clinical implications and future directions

LEUKEMIA & LYMPHOMA

Authors: Luo, Ping; Jing, Wei; Yi, Kezhen; Wu, Sanyun; Zhou, Fuling

Abstract

The Wilms' tumor 1 (WT1) gene is an important regulatory molecule that plays a vital role in cell growth and development. Initially, knowledge of WT1 was mostly limited to Wilms' tumor. Over the past years, numerous studies have shown that WT1 is aberrant expressed or mutated in hematopoietic malignancies, including acute leukemia (AL), myelodysplastic syndrome (MDS) and chronic myelogenous leukemia (CML). Currently, many studies focus on exploring the role of WT1 in hematopoietic malignancies. Such studies improve the understanding of hematopoietic malignancies, and the collection of data about WT1 expression or mutation in hematopoietic malignancies over the past years can facilitate the risk stratification of hematopoietic malignancies. In this review, we highlight the important role of WT1 in hematopoietic malignancies, discuss its potential clinical applications as a minimal residual disease (MRD) and prognostic biomarker, and evaluate the possible therapy target of WT1 in hematopoietic malignancies.

Impact of ABCB1 Gene (C3435T/A2677G) Polymorphic Sequence Variations on the Outcome of Patients with Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia in Kashmiri Population: A Case-Control Study

INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION

Authors: Baba, Shahid M.; Pandith, Arshad A.; Shah, Zafar A.; Geelani, Sajad A.; Mir, Mohammad Muzaffar; Bhat, Javid Rasool; Bhat, Gul Mohammad

Abstract

Inherited polymorphic sequence variations in drug transport genes likeABCB1impact a portion of patients with hematologic malignancies that show intrinsic or acquire resistance to treatment. Keeping in view inter-individual sensitivities for such drugs, we through this case-control study tested whetherABCB1C3435T and G2677T polymorphisms have any influence on the risk and treatment response in patients with chronic myeloid leukemia (CML) and B-acute lymphoblastic leukemia (B-ALL). Genotyping forABCB1polymorphisms was performed by polymerase chain reaction-restriction fragment length polymorphism in 100 CML and 80 B-ALL patients along with 100 age and gender matched healthy controls.ABCB1C3435T and G2677T polymorphism showed no association with CML. Genotype distribution revealed significant higher frequency of TT genotype for both SNPs in B-ALL cases and associated with increased B-ALL risk (OR 2.5,p = 0.04 for 3435TT; OR 2.4,p = 0.04 for 2677TT). There was no significant difference in genotype frequency of 3435C > T and 2677G > T among resistant and responsive groups for the two leukemia types. Kaplan-Meier survival plots revealed significantly lower event free survival in CML and B-ALL patients that were carriers of 3435TT genotype (p < 0.05). Multivariate analysis considered 3435TT genotype as independent risk factor for imatinib resistance in CML cases (HR 6.24,p = 0.002) and increased relapse risk in B-ALL patients (HR 4.51,p = 0.03). The current study provides preliminary evidence of a significant association between variant TT genotype and increased B-ALL risk. Also, results suggest thatABCB13435TT genotype increases imatinib resistance in CML and influence therapeutic outcome in B-ALL.